Sublingual methadone for the management of cancer-related procedural pain in inpatients: a phase II multicentre, open label, feasibility study

Alberta Cancer Board (Canada)0 个研究点目标入组 20 人开始时间: 2006年7月6日最近更新: 2019年2月11日

适应症

试验速览

暂无简介。

•1. Pain due to cancer or its treatment
•2. Controlled baseline pain
•3. Episodes of predictable, treatment-related pain every day that are 4/10 in severity or greater, last ten minutes or longer, or episodes of breakthrough pain not related to cancer treatment, and are responsive to short-acting oral opioids such as morphine or hydromorphone
•4. Able to hold a volume of 1.0 cc of water under the tongue for a two-minute period
•5. Able to provide written, informed consent
•6. Able to fill out the study forms, and must be an inpatient

•1. Severe underlying respiratory disease such that the investigator is wary about the risk of respiratory failure from modest doses of opioid
•2. Prior sensitivity to methadone
•3. Currently taking methadone
•4. Clinically unstable or a life expectancy of less than one month making completion of the trial unlikely
•5. Patients who do not have an understanding of English enough to provide written, informed consent

发起方

Alberta Cancer Board (Canada)